10-Q 1 celz_10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of regi ...

10-Q 1 celz_10q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of registran ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (Exact name of registrant as specified in its charter) Nevada 8 ...

Financial Performance - For the year ended December 31, 2019, the company generated $165,500 in gross revenue, an increase of $41,100 or 33.0% compared to $124,400 in 2018, attributed to the commercialization of the CaverStem® procedure [125]. - Cost of goods sold decreased to $45,499 for the year ended December 31, 2019, down $24,876 or 35.3% from $70,375 in 2018, due to increased sales and lower per unit costs [126]. - The company achieved a gross profit of $120,001 for the year ended December 31, 2019, compared to a gross loss of $54,025 in 2018, marking an increase of $65,976 or 122.1% [127]. - Total revenues for the year ended December 31, 2019, were $165,500, compared to $124,400 for the year ended December 31, 2018, representing a 33.1% increase [156]. - Gross profit for the year ended December 31, 2019, was $120,001, up from $54,025 in 2018, indicating a significant improvement in profitability [156]. - Operating loss for the year ended December 31, 2019, was $(1,130,168), slightly higher than the $(1,114,225) loss reported in 2018 [156]. - Net loss for the year ended December 31, 2019, was $(8,483,673), compared to $(13,655,653) in 2018, showing a reduction in losses by approximately 37.5% [156]. - The company reported a net loss of $8,483,673 for the year ended December 31, 2019, an improvement from a net loss of $13,655,653 in 2018, representing a reduction of approximately 38.5% [158]. Expenses - General and administrative expenses rose to $1,223,219 for the year ended December 31, 2019, an increase of $172,734 or 16.4% from $1,050,485 in 2018, primarily due to marketing and travel expenses [128]. - Research and development expenses were $0 for the year ended December 31, 2019, a decrease of $96,621 or 100% from $96,621 in 2018, due to the completion of clinical trials [129]. - Cash used in operating activities was $1,213,093 for 2019, compared to $1,052,270 in 2018, indicating an increase of about 15.3% in cash outflow [158]. - The company incurred cash payments for interest totaling $18,177 in 2019, up from $6,712 in 2018, representing an increase of approximately 170.5% [158]. Assets and Liabilities - Total current assets decreased from $313,656 in 2018 to $94,248 in 2019, a decline of 69.9% [153]. - Total liabilities increased significantly from $4,471,798 in 2018 to $8,602,302 in 2019, representing a 92.5% increase [153]. - The accumulated deficit as of December 31, 2019, was $(25,565,006), compared to $(17,081,333) in 2018, indicating an increase in the deficit of 49.8% [153]. - The company reported derivative liabilities of $6,847,877 in 2019, up from $3,227,382 in 2018, reflecting a 112.5% increase [153]. - The total stockholders' deficit as of December 31, 2019, was $8,071,499, compared to $3,994,637 in 2018, indicating an increase of approximately 102.5% [159]. - The company has a negative working capital of $8,508,054 as of December 31, 2019, raising substantial doubt about its ability to continue as a going concern [171]. Future Plans and Market Strategy - The company plans to continue expanding the market for CaverStem® and FemCelz® procedures, launch the StemSpine procedure, and file an IND application for Amniostem over the next 12 months [122]. - The company intends to fund its operations through sales of disposable stem cell concentration kits and seeks investments to meet cash flow requirements [136]. - The company plans to raise additional funds through loans or sales of common stock to address its financial challenges [171]. Stock and Equity - The weighted average number of shares outstanding for basic and diluted calculations increased from 3,906,224 in 2018 to 10,343,162 in 2019, a rise of 164.5% [156]. - The Company issued $1,572,400 in convertible notes during 2019, with net proceeds of $1,302,795, maturing from February to October 2020 [218]. - As of December 31, 2019, the Company had potential future dilution of approximately 176 million shares from convertible notes payable [227]. - The Company has reserved 2,000,000 shares under its 2016 Stock Incentive Plan for employee and consultant compensation [228]. - The Company converted $150,000 of debt into 3,000,000 shares of Series A Preferred Stock in 2018 [208]. Tax and Valuation - The company reported a net provision for income tax of $0 for 2019, with a federal tax provision of $(272,800) and a state tax provision of $(75,792) [242]. - As of December 31, 2019, the company had federal and state gross net operating loss carryforwards of approximately $5.3 million, expiring in years beginning in 2036 [242]. - The company maintains a full valuation allowance on its net deferred tax assets due to a history of cumulative losses and expected future losses [243]. Impact of COVID-19 - The company experienced a reduction in revenues due to COVID-19, with non-essential procedures placed on hold, but expects existing orders to resume once operations normalize [248].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-53500 | --- | --- | --- | |--------------------------------|-------------------------------------- ...

Revenue and Profit - Gross revenue for the three-month period ended June 30, 2019, was $61,600, an increase of $56,800 or 1,183% compared to $4,800 in the same quarter last year [142]. - Gross profit for the three-month period ended June 30, 2019, was $42,400, reflecting an increase of $40,128 or 1,766% from $2,272 in the comparable quarter a year ago [144]. - For the six-month period ended June 30, 2019, gross revenue was $112,400, up $98,000 or 681% from $14,400 in the same period last year [149]. Net Loss and Expenses - The net loss for the three-month period ended June 30, 2019, was $88,233, significantly reduced from $6,432,404 in the comparable quarter a year ago [148]. - Research and development expenses for the three-month period ended June 30, 2019, were $0, a decrease of 100% from $4,200 in the same quarter last year [146]. - General and administrative expenses for the six-month period ended June 30, 2019, totaled $594,546, an increase of $84,000 or 17% compared to $510,546 in the same period last year [152]. Cash Position and Operating Activities - The company had approximately $204,112 in cash on hand as of June 30, 2019, with an estimated monthly cash burn rate of $100,000 [140]. - Net cash used in operating activities for the six-month period ended June 30, 2019, was $602,380, an increase of $192,678 or 47% from $409,702 in the comparable period last year [161]. - The company raised $689,890 through the issuance of convertible debt in the six-month period ended June 30, 2019 [162]. Going Concern - The company has a working capital deficit of $2,789,894 as of June 30, 2019, raising substantial doubt about its ability to continue as a going concern [163].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 000-53500 Creative Medical Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Nevada 8 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 000-53500 | --- | --- | |-----------------------------------------------------------------------------------|-------- ...